SARS-CoV-2 Neutralizing Antibody ELISA Kit (Omicron BA.4 / BA.5 / BF.7 / BQ.1 / XBB.1.5)
Référence GTX538288
Conditionnement : 96test
Marque : Genetex
Application | Neutralizing/Inhibition |
---|---|
Reactivity | SARS Coronavirus 2 |
Package | 96 test |
View product citations for antibody GTX538288 on CiteAb
PRODUCT
Summary
The GeneTex SARS-CoV-2 Neutralizing Antibody ELISA Kit (Omicron BA.4/5 / BF.7 / BQ.1 / XBB1.5) is an in vitro assay for qualitative SARS-CoV-2 NAb screening. The kit includes recombinant His-tagged SARS-CoV-2 Spike RBD proteins for the Omicron variant BA.4/5, Omicron variant BF.7, Omicron variant BQ.1, and Omicron variant XBB 1.5, for Omicron variant-specific neutralization analysis.
APPLICATION
PROPERTIES
Storage
The entire kit can be stored at 2-8ºC for up to 6 months.
Conjugation
Horseradish peroxidase(HRP)
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
TARGET
DATA IMAGES
GTX538288 Neutralizing/Inhibition ImageInhibition analysis of SARS-CoV-2 (COVID-19) Spike RBD antibody [HL1004] (GTX635793) (104-13333 pM) using SARS-CoV-2 Neutralizing Antibody ELISA Kit (Omicron BA.4 / BA.5 / BF.7 / BQ.1 / XBB.1.5). |
GTX538288 Neutralizing/Inhibition ImageInhibition analysis of SARS-CoV-2 (COVID-19) Spike RBD Omicron antibody [HL1866] (GTX637591) (104-13333 pM) using SARS-CoV-2 Neutralizing Antibody ELISA Kit (Omicron BA.4 / BA.5 / BF.7 / BQ.1 / XBB.1.5). |
GTX538288 Neutralizing/Inhibition Image
|
Application Reference
Laquintana V et al. Front Immunol 2023; 14 : 1221587 Dynamics of humoral and cellular response to three doses of anti-SARS-CoV-2 BNT162b2 vaccine in patients with hematological malignancies and older subjects.
Chen WC et al. Vaccines (Basel) 2023; 11 (9) COVID-19 Bivalent Booster in Pregnancy: Maternal and Neonatal Antibody Response to Omicron BA.5, BQ.1, BF.7 and XBB.1.5 SARS-CoV-2.
REVIEW
Application Reference
Laquintana V et al. Front Immunol 2023; 14:1221587 Dynamics of humoral and cellular response to three doses of anti-SARS-CoV-2 BNT162b2 vaccine in patients with hematological malignancies and older subjects.
Chen WC et al. Vaccines (Basel) 2023; 11 (9) COVID-19 Bivalent Booster in Pregnancy: Maternal and Neonatal Antibody Response to Omicron BA.5, BQ.1, BF.7 and XBB.1.5 SARS-CoV-2.
SDS | |
---|---|
SDS-GTX ELISA kitv2.1_MSDS.pdf |